Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 15Terminated 9Recruiting 8Active not recruiting 6Withdrawn 3Unknown 3Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 18Thoracic 14CNS 12Genitourinary 8Breast 5Dermatologic 4Head & Neck 3Tumor-Agnostic 2Lymphoid 2Sarcoma 1Other solid neoplasm 1Gynecologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3

Interventions

Cisplatin 21pembrolizumab 12Cetuximab 12Radiotherapy 11Carboplatin 10Nivolumab 9Radiotherapy, Intensity-Modulated 8Fluorouracil 8durvalumab 5Standard of Care 5epacadostat 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Drug Therapy 4Cyclophosphamide 4X-Rays 3Radiosurgery 3Radiation 3Practice Guidelines as Topic 3Panitumumab 3Gene Expression Profiling 3Docetaxel 3Biopsy 3fluoromisonidazole 2fludarabine 2cemiplimab 2aldesleukin 2Venlafaxine Hydrochloride 2Thyroxine 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Radiosurgery × Head & Neck × Clear all
NCT03169764 2025-02-24

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04834349 2023-09-13

Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01586182 2015-09-04

Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma

Dana-Farber Cancer Institute

Phase 1/2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡